ClinicalTrials.gg
CompletedNCT01275131Updated Jul 25, 2014Results posted

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

A Phase 1 interventional study of Insulin aspart and Recombinant human hyaluronidase PH20 (rHuPH20) in Type 1 Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-25.

Sponsored by Halozyme Therapeutics · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
582nd of 1,242
45 · median 40
Started
2011
with 46 others
Phase 1
147 of 1,458
11 open now
Registered
362nd of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 582nd largest by enrollment of the 1,242 interventional ones that give a count, is one of 47 that started in 2011, is one of 147 in phase 1, and was the 362nd registered.

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if recombinant human hyaluronidase PH20 (rHuPH20) will change the exposure and action of approved insulin analogs when given by continuous subcutaneous insulin infusion (CSII) in participants with Type 1 diabetes mellitus (T1DM).

This study is divided into Stage 1, 2, and 3. Stage 3 was started chronologically before Stage 2 and, prior to performing Stage 2, the Sponsor made the decision to terminate Stage 2. Stage 2 was not initiated due to a strategic business decision and termination was not based on safety or efficacy concerns. No participants were enrolled in Stage 2.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Insulin analog
  • Type 1 diabetes mellitus
  • Pharmacokinetic
  • Glucodynamic
  • Phase 1
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 to 65 years, inclusive. Females of must use a standard and effective means of for the duration of the study.
  2. Non-smoking participants with Type 1 diabetes mellitus (T1DM) treated with insulin for greater than or equal to 12 months. Non-smoking means abstinence from cigarettes and cigars for 3 months and negative cotinine screening tests.
  3. (BMI) 18.0 to 35.0 kilograms per meter squared (kg/m\^2), inclusive.
  4. Glycosylated (HbA1c) ≤10 % based on local laboratory results.
  5. Fasting C-peptide \<0.6 nanograms per milliliter (ng/mL).
  6. Current treatment with insulin \<90 units per day (U/d).
  7. Routine use of continuous subcutaneous insulin infusion (CSII) as the primary route of insulin administration.
  8. Participant should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug infusions and assessments required in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to any component of any of the study drugs in this trial.
  2. Previous enrollment in this trial (Exception: participants in Stage 1 are permitted to participate in Stage 2).
  3. Use of drugs that may interfere with the interpretation of trial results or are known to cause interference with insulin action, glucose utilization, or recovery from hypoglycemia. Participants taking maintenance doses of blood thinners (eg, Coumadin or heparin) will be excluded.
  4. Use of any long-acting insulin injection within 72 hours of Stage 1 or Stage 3.
  5. Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator.
  6. Current addiction to alcohol or substances of abuse as determined by the Investigator.
  7. Blood donation or phlebotomy (>500 milliliters [mL]) within the previous 8 weeks of Screening. This applies both to new participants and to participants who have participated in Stage 1 and who wish to continue in Stage 2.
  8. Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives, or barrier methods).
  9. Symptomatic gastroparesis.
  10. Receipt of any drug within 4 weeks of Stage 1 or Stage 2.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Active comparator
    Stage 1: Insulin aspart first, then insulin aspart-rHuPH20

    Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4. After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8.

    Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart

    Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4. After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8.

    Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Stage 3: Insulin aspart first, then insulin aspart + rHuPH20

    Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp. After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp.

    Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart

    Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp . After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp.

    Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

Interventions

06

What researchers measure

Primary outcomes

  1. Early Insulin Exposure (%AUC[0-60]), Stage 1

    Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}\]) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.

    Time frame: 10 minutes predose up to 60 minutes postdose

  2. Early Exposure to Insulin (%AUC[0-60]), Stage 3

    Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.

    Time frame: 10 minutes predose up to 60 minutes postdose on Days 2/7, 3/8, and 5/10

Secondary outcomes

  1. Maximum Glucose Infusion Rate (GIRmax), Stage 1

    Maximum glucose infusion rates (GIRmax) for Stage1 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 0 up to 360 minutes postdose on Day 2/6 and Day 4/8

  2. Maximum Glucose Infusion Rate (GIRmax), Stage 3

    Maximum glucose infusion rates (GIRmax) for Stage 3 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10

  3. Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 1

    Time to first occurrence of maximum glucose infusion rate (tGIRmax) for Stage 1 is presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 0 up to 360 minutes postdose on Day 2/6 and Day 4/8

  4. Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 3

    Time to first occurrence of maximum glucose infusion rate (tGIRmax) for Stage 3 is presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10

  5. Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 1

    Early and late times to 50% maximum glucose infusion rate (tGIR50%max) for Stage 1 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 0 up to 360 minutes postdose on day 2/6 and Day 4/8

  6. Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 3

    Early and late time to 50% maximum glucose infusion rates (tGIR50%max) for Stage 3 studies are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10

  7. Time to 50% Total Glucose Infused (50%Gtot), Stage 1

    Time to 50% total glucose infused (50%Gtot) is presented for Stage 1. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 0 up to 360 minutes postdose on Day 2/6 and Day 4/8

  8. Time to 50% Total Glucose Infused (50%Gtot), Stage 3

    Time to 50% of total glucose infused (50%Gtot) is presented for Stage 3. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10

  9. Area Under the Glucose Concentration Curve (AUC[0-360]), Stage 1

    Area under the glucose concentration curve for 0 to 360 minutes (AUC\[0-360\]) from Stage 1 is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 30 minutes predose up to 360 minutes postdose on Day 2/6 and Day 4/8

  10. Area Under the Glucose Concentration Curve (AUC[0-360]), Stage 3

    Area under the glucose concentration curve from 0 to 360 minutes (AUC\[0-360\]) for Stage 3 studies is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 30 minutes predose up to 360 minutes postdose Days 2/7, 3/8, and 5/10

  11. Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 1

    Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]) for Stage 1. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 10 minutes predose up to 360 minutes postdose on Day 2/6 and Day 4/8

  12. Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3

    Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]) for Stage 3. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

    Time frame: 10 minutes predose up to 360 minutes postdose on Days 2/7, 3/8, and 5/10

07

Results

Posted Jul 25, 2014

Participant flow

Period 1
Participant flow — Period 1
MilestoneStage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin AspartStage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart
Started1191312
Received at least one dose of study drug1191312
Completed991010
Not completed2032
Withdrew: Withdrawal by subject1032
Withdrew: Physician decision1000
5- to 14-Day Washout Period
Participant flow — 5- to 14-Day Washout Period
MilestoneStage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin AspartStage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart
Started991010
Completed991010
Not completed0000
Period 2 (Crossover)
Participant flow — Period 2 (Crossover)
MilestoneStage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin AspartStage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart
Started991010
Completed8898
Not completed1112
Withdrew: Adverse event0100
Withdrew: Withdrawal by subject1012

Outcome measures

PrimaryEarly Insulin Exposure (%AUC[0-60]), Stage 1

Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}\]) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.

Time frame:
10 minutes predose up to 60 minutes postdose
Reported as:
Mean · Percentage of AUC(0-360)
Early Insulin Exposure (%AUC[0-60]), Stage 1
Percentage of AUC(0-360)Stage 1: Insulin Aspart AloneStage 1: Insulin Aspart-rHuPH20
Stage 1, Day 2/620.99 ± 6.3734.94 ± 9.48
Stage 1, Day 4/832.83 ± 14.6650.97 ± 13.91
Statistical analysis
  • Stage 1: Insulin Aspart Alone vs Stage 1: Insulin Aspart-rHuPH20 · Mixed Models Analysis · p = 0.0009 · Least squares mean difference: 13.95 · 90% CI 7.37 to 20.54A mixed model with fixed effects for treatment, day, and interaction of treatment with day was performed using a compound symmetric covariance matrix.
  • Stage 1: Insulin Aspart Alone vs Stage 1: Insulin Aspart-rHuPH20 · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 18.14 · 90% CI 11.55 to 24.72A mixed model with fixed effects for treatment, day, and interaction of treatment with day was performed using a compound symmetric covariance matrix.
SecondaryMaximum Glucose Infusion Rate (GIRmax), Stage 1

Maximum glucose infusion rates (GIRmax) for Stage1 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
0 up to 360 minutes postdose on Day 2/6 and Day 4/8
Reported as:
Mean · Milligrams/kilogram/minute
Maximum Glucose Infusion Rate (GIRmax), Stage 1
Milligrams/kilogram/minuteStage 1: Insulin Aspart AloneStage 1: Insulin Aspart-rHuPH20
Stage 1, Day 2/613.37 ± 4.2312.51 ± 3.19
Stage 1, Day 4/811.88 ± 3.6411.52 ± 3.67
PrimaryEarly Exposure to Insulin (%AUC[0-60]), Stage 3

Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.

Time frame:
10 minutes predose up to 60 minutes postdose on Days 2/7, 3/8, and 5/10
Reported as:
Mean · Percentage of AUC(0-360)
Early Exposure to Insulin (%AUC[0-60]), Stage 3
Percentage of AUC(0-360)Stage 3: Insulin Aspart AloneStage 3: Insulin Aspart + rHuPH20
Stage 3, Day 2/715.70 ± 6.3832.11 ± 10.91
Stage 3, Day 3/822.29 ± 5.4336.39 ± 9.43
Stage 3, Day 5/1027.31 ± 10.4932.64 ± 11.32
Statistical analysis
  • Stage 3: Insulin Aspart Alone vs Stage 3: Insulin Aspart + rHuPH20 · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 16.41 · 90% CI 11.86 to 20.97Mixed model with fixed effects for treatment, day, and interaction of treatment with day. A compound symmetric covariance matrix was assumed.
  • Stage 3: Insulin Aspart Alone vs Stage 3: Insulin Aspart + rHuPH20 · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 14.10 · 90% CI 9.55 to 18.65Mixed model with fixed effects for treatment, day, and interaction of treatment with day. A compound symmetric covariance matrix was assumed.
  • Stage 3: Insulin Aspart Alone vs Stage 3: Insulin Aspart + rHuPH20 · Mixed Models Analysis · p = 0.0552 · Least squares mean difference: 5.32 · 90% CI 0.77 to 9.88Mixed model with fixed effects for treatment, day, and interaction of treatment with day. A compound symmetric covariance matrix was assumed.
SecondaryMaximum Glucose Infusion Rate (GIRmax), Stage 3

Maximum glucose infusion rates (GIRmax) for Stage 3 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Reported as:
Mean · Milligrams/kilogram/minute
Maximum Glucose Infusion Rate (GIRmax), Stage 3
Milligrams/kilogram/minuteStage 3: Insulin Aspart AloneStage 3: Insulin Aspart + rHuPH20
Stage 3, Day 2/79.58 ± 2.2812.63 ± 3.88
Stage 3, Day 3/810.07 ± 3.3612.4 ± 3.39
Stage 3, Day 5/109.97 ± 3.5310.76 ± 3.35
SecondaryTime to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 1

Time to first occurrence of maximum glucose infusion rate (tGIRmax) for Stage 1 is presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
0 up to 360 minutes postdose on Day 2/6 and Day 4/8
Reported as:
Mean · Minutes
Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 1
MinutesStage 1: Insulin Aspart AloneStage 1: Insulin Aspart-rHuPH20
Stage 1, Day 2/6115.38 ± 59.21102.38 ± 38.28
Stage 1, Day 4/892.50 ± 24.7184.31 ± 25.89
SecondaryTime to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 3

Time to first occurrence of maximum glucose infusion rate (tGIRmax) for Stage 3 is presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Reported as:
Mean · Minutes
Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 3
MinutesStage 3: Insulin Aspart AloneStage 3: Insulin Aspart + rHuPH20
Stage 3, Day 2/7127.65 ± 60.0278.53 ± 27.04
Stage 3, Day 3/8135.24 ± 73.0079.47 ± 42.57
Stage 3, Day 5/10117.76 ± 75.2079.53 ± 42.99
SecondaryTime to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 1

Early and late times to 50% maximum glucose infusion rate (tGIR50%max) for Stage 1 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
0 up to 360 minutes postdose on day 2/6 and Day 4/8
Reported as:
Mean · Minutes
Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 1
MinutesStage 1: Insulin Aspart AloneStage 1: Insulin Aspart-rHuPH20
Early tGIR50%max, Stage 1, Day 2/646.50 ± 18.0834.88 ± 17.92
Late tGIR50%max, Stage 1, Day 2/6162.19 ± 56.78158.06 ± 52.58
Early tGIR50%max, Stage 1, Day 4/835.19 ± 28.5439.75 ± 18.71
Late tGIR50%max, Stage 1, Day 4/8132.63 ± 47.37114.19 ± 29.05
SecondaryTime to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 3

Early and late time to 50% maximum glucose infusion rates (tGIR50%max) for Stage 3 studies are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Reported as:
Mean · Minutes
Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 3
MinutesStage 3: Insulin Aspart AloneStage 3: Insulin Aspart + rHuPH20
Early tGIR50%max, Stage 3, Day 2/758.47 ± 17.5331.06 ± 20.73
Late tGIR50%max, Stage 3, Day 2/7144.18 ± 61.4498.71 ± 39.87
Early tGIR50%max, Stage 3, Day 3/832.59 ± 22.8831.53 ± 21.27
Late tGIR50%max, Stage 3, Day 3/8153.41 ± 65.35102.88 ± 44.57
Early tGIR50%max, Stage 3, Day 5/1027.29 ± 18.4028.88 ± 21.97
Late tGIR50%max, Stage 3, Day 5/10136.88 ± 73.39110.59 ± 55.10
SecondaryTime to 50% Total Glucose Infused (50%Gtot), Stage 1

Time to 50% total glucose infused (50%Gtot) is presented for Stage 1. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
0 up to 360 minutes postdose on Day 2/6 and Day 4/8
Reported as:
Mean · Minutes
Time to 50% Total Glucose Infused (50%Gtot), Stage 1
MinutesStage 1: Insulin Aspart AloneStage 1: Insulin Aspart-rHuPH20
Stage 1, Day 2/6156.13 ± 18.70134.94 ± 18.28
Stage 1, Day 4/8137.38 ± 22.21115.25 ± 14.50
SecondaryTime to 50% Total Glucose Infused (50%Gtot), Stage 3

Time to 50% of total glucose infused (50%Gtot) is presented for Stage 3. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Reported as:
Mean · Minutes
Time to 50% Total Glucose Infused (50%Gtot), Stage 3
MinutesStage 3: Insulin Aspart AloneStage 3: Insulin Aspart + rHuPH20
Stage 3, Day 2/7174.59 ± 25.86124.18 ± 22.03
Stage 3, Day 3/8154.06 ± 24.02120.00 ± 17.12
Stage 3, Day 5/10146.59 ± 28.63130.18 ± 23.54
SecondaryArea Under the Glucose Concentration Curve (AUC[0-360]), Stage 1

Area under the glucose concentration curve for 0 to 360 minutes (AUC\[0-360\]) from Stage 1 is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
30 minutes predose up to 360 minutes postdose on Day 2/6 and Day 4/8
Reported as:
Mean · Picomoles*minutes/liter
Area Under the Glucose Concentration Curve (AUC[0-360]), Stage 1
Picomoles*minutes/literStage 1: Insulin Aspart AloneStage 1: Insulin Aspart-rHuPH20
Stage 1, Day 2/61978.08 ± 631.891977.02 ± 795.79
Stage 1, Day 4/81598.40 ± 546.001324.31 ± 500.04
SecondaryArea Under the Glucose Concentration Curve (AUC[0-360]), Stage 3

Area under the glucose concentration curve from 0 to 360 minutes (AUC\[0-360\]) for Stage 3 studies is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
30 minutes predose up to 360 minutes postdose Days 2/7, 3/8, and 5/10
Reported as:
Mean · Picomoles*minutes/liter
Area Under the Glucose Concentration Curve (AUC[0-360]), Stage 3
Picomoles*minutes/literStage 3: Insulin Aspart AloneStage 3: Insulin Aspart + rHuPH20
Stage 3, Day 2/71197.60 ± 385.441509.38 ± 541.45
Stage 3, Day 3/81368.81 ± 424.161405.75 ± 516.85
Stage 3, Day 5/101289.22 ± 486.031369.97 ± 462.78
SecondaryDuration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 1

Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]) for Stage 1. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
10 minutes predose up to 360 minutes postdose on Day 2/6 and Day 4/8
Reported as:
Mean · Ratio
Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 1
RatioStage 1: Insulin Aspart AloneStage 1: Insulin Aspart-rHuPH20
Stage 1, Day 2/6163.63 ± 14.70146.51 ± 16.30
Stage 1, Day 4/8147.50 ± 23.86132.60 ± 15.55
SecondaryDuration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3

Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]) for Stage 3. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.

Time frame:
10 minutes predose up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Reported as:
Mean · ratio
Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3
ratioStage 3: Insulin Aspart AloneStage 3: Insulin Aspart + rHuPH20
Stage 3, Day 2/7180.39 ± 18.72138.59 ± 18.41
Stage 3, Day 3/8164.65 ± 19.97135.71 ± 17.30
Stage 3, Day 5/10156.14 ± 26.38145.81 ± 16.42

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1: Insulin Aspart—0/20 (0%)16/20 (80%)
Stage 1: Insulin Aspart-rHuPH20—0/18 (0%)13/18 (72.2%)
Stage 3: Insulin Aspart—0/23 (0%)14/23 (60.9%)
Stage 3: Insulin Aspart + rHuPH20—0/22 (0%)12/22 (54.5%)
Most frequent other events
Showing 10 of 46
Most frequent other events
EventStage 1: Insulin AspartStage 1: Insulin Aspart-rHuPH20Stage 3: Insulin AspartStage 3: Insulin Aspart + rHuPH20
HeadacheNervous system disorders7/203/184/233/22
Incision site haemorrhageInjury, poisoning and procedural complications3/203/180/230/22
Injection site erythemaGeneral disorders2/202/180/230/22
Infusion site painGeneral disorders0/202/181/231/22
Injection site haemorrhageGeneral disorders0/202/180/231/22
Injection site pruritusGeneral disorders2/200/180/230/22
Infusion site haematomaGeneral disorders2/201/180/231/22
Infusion site extravasationGeneral disorders0/201/180/232/22
NauseaGastrointestinal disorders1/201/180/232/22
AnaemiaBlood and lymphatic system disorders0/201/180/232/22

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin AspartStage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin AspartTotal
Mean31.3 ± 6.3944.6 ± 9.0035.5 ± 9.5032.3 ± 10.2935.44 ± 9.95
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin AspartStage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin AspartTotal
Female637622
Male566623
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin AspartStage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin AspartTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00112
White119111142
More than one race00000
Unknown or Not Reported00101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin AspartStage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin AspartTotal
Hispanic or Latino11002
Not Hispanic or Latino108131243
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin AspartStage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin AspartTotal
United States119131245
08

Study locations

1 site
  • Profil Institute for Clinical Research
    Chula Vista, California 91911, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2011
First posted
Jan 12, 2011
Start
Jan 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Jul 25, 2014
Last update
Jul 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01275131
Responsible party
Sponsor
First posted
Jan 12, 2011
Start date
Jan 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Jul 25, 2014
Last update
Jul 25, 2014

Study contacts

Linda Morrow, MD
principal investigator · Profil Institute for Clinical Research, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion